Amiodarone induced pulmonary fibrosis in infancy.
We report a case of pulmonary fibrosis in an infant receiving amiodarone for treatment of intractable atrioventricular reentrant tachycardia secondary to Wolff-Parkinson-White syndrome. At 9 months, a screening chest radiograph showed a diffuse interstitial infiltrate in an asymptomatic, thriving infant. Amiodarone was discontinued and the pulmonary fibrosis resolved gradually over 6 months. This case documents the first report of amiodarone induced pulmonary fibrosis in the pediatric age group. We speculate that as amiodarone is used more frequently to manage pediatric arrhythmias, pulmonary fibrosis, a known complication of this antiarrhythmia in adults may be seen with increasing frequency in children.
Bowers
P N
PN
Section of Pediatric Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Fields
J
J
Schwartz
D
D
Rosenfeld
L E
LE
Nehgme
R
R
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D015716:Electrocardiography, Ambulatory; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011433:Propranolol / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D013902:Radiography, Thoracic; D013617:Tachycardia, Supraventricular / Q000151:congenital / Q000188:drug therapy / Q000503:physiopathology; D014057:Tomography, X-Ray Computed
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D011433:Propranolol; D000638:Amiodarone